The MagnetisMM studies are committed to finding potential treatment options

Your patients don’t have to take on multiple myeloma alone
We know it takes a full support system to take on multiple myeloma. And we’re here to explore a potential way to fight it with you.

The MagnetisMM clinical research studies will evaluate the safety and effectiveness of a study medicine, elranatamab, in people with multiple myeloma (MM). The investigational study medicine, elranatamab, is a bispecific antibody designed to bind to BCMA which is highly expressed on the surface of multiple myeloma cells, and the CD3 receptor found on the surface of cancer-fighting T cells, bridging them together to activate an immune response

HCP Contact Form

Do you have potentially eligible patients with multiple myeloma in your care? 

Please fill out the contact form below and a field medical team member will get in touch with you.

HCP Contact Form

Each MagnetisMM – study will have its own unique requirements for who may participate (eligibility criteria).  

 

These requirements may include your patient’s stage of multiple myeloma as well as any previous treatments they may have received. 

 

To find out if your patients may be eligible to join a MagnetisMM study that is actively recruiting, please complete the Contact Form below and a field medical team member will contact you.

About the study medicine

Blood cancers remain one of the greatest health challenges of our lifetime. In 2020, more than 1 million people worldwide were diagnosed with a blood cancer. And while no two blood cancers are alike – whether leukemia, lymphoma, or myeloma — treatments vary greatly.

 

The needs of patients with blood cancers are unique and differ from those with solid tumors. They are challenging to treat and therefore they require a specialized treatment approach to meet their needs.

 

Over the last decade, we’ve made strides in blood cancers, but our work is far from finished. We seek to invest in game-changing science to deliver tomorrow’s breakthroughs for diseases that represent significant areas of need for innovation. While there are several approved myeloma drugs, the outcomes remain dire, and there’s still a substantial unmet need for people living with the second most common blood cancer. In 2022, approximately 34,470 new cases of multiple myeloma will be diagnosed in the U.S. and over 176,000 globally. In the U.S., the median survival is just over 5 years, and most patients receive four or more lines of therapy.

 

There are several reasons why BCMA is a promising immunotherapeutic target

  • Selectively expressed on plasma cells:
    • BCMA is a transmembrane glycoprotein of the tumor necrosis factor receptor (TNFR) superfamily
    • Preferentially expressed on mature B lymphocytes and overexpressed on multiple myeloma cells
    • Minimal expression on hematopoietic stem cells or nonhematopoietic tissue
  • Associated with disease progression: BCMA overexpression and activation can upregulate various pathways and enhance expression of genes critical for survival, growth, metastasis, and immunosuppression.
  • Associated with drug resistance: BCMA overexpression leads to enhanced expression of interleukin 10 (IL-10),  programmed death-ligand 1 (PD-L1), and other immune-regulatory genes that are thought to suppress the immune response in the bone marrow microenvironment. Additionally in MM patients, BCMA expression is increased on plasmacytoid dendritic cells which promote survival and development of drug resistance in MM cells.
 
In a Phase 1 study, elranatamab as a single agent, administered either Q1W or Q2W, had a manageable safety profile for patients with relapsed or refractory (RR) MM. Across the efficacious dose range, elranatamab achieved confirmed objective response rate (ORR) of 70% and complete response/stringent complete response rate of 30%, with confirmed ORR of 83% at the recommended phase 2 dose. Importantly, elranatamab induces deep and durable clinical responses in RR MM patients with and without prior BCMA-targeted therapy and 100% minimal residual disease (MRD) negativity in MRD evaluable patients. These results, along with emerging combination data, support continued development of elranatamab as a single agent and in combination with standard therapies for MM.

Learn more about BCMA as an immunotherapeutic target

Learn more